𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II clinical study of mAMSA in small cell carcinoma of the lung

✍ Scribed by P. J. Dady; A. -P. Sappino; A. Rudd; I. E. Smith

Publisher
Springer
Year
1981
Tongue
English
Weight
167 KB
Volume
6
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis

Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppression. No responses were observed. Median survival from the start of treatment with mAMSA was 5 weeks.

πŸ“œ SIMILAR VOLUMES

Phase-II study of vindesine and hexameth
Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung
✍ Rudolf A. Joss; Jean-Paul Obrecht; Walter F. Jungi; Pierre Alberto; Christian Sa πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 163 KB

Twenty-five patients with measurable small cell lung cancer relapsing after first-line chemotherapy were treated with vindesine 3 mg/m2 IV on days 1 and 8 and hexamethylmelamine 100 mg/m2 PO on days 1-14, repeated every 3 weeks. Among 18 fully evaluable patients there was 1 partial remission lasting